Bio

AnPac Bio Announces Appointment of New Chief Financial Officer

Tuesday, June 2, 2020 - 10:00pm

Mr. Tang will succeed to Ms. Yu (Rain) Zhang, who resigned as the Chief Financial Officer of the Company for personal reasons effective on May 31, 2020.

Key Points: 
  • Mr. Tang will succeed to Ms. Yu (Rain) Zhang, who resigned as the Chief Financial Officer of the Company for personal reasons effective on May 31, 2020.
  • Prior to joining AnPac Bio, Mr. Tang served as a global internal auditor at Natuzzi S.p.A (Italy) from 2016 to 2019.
  • His strong financial background will help him to make an immediate impact at AnPac Bio, said Dr. Chris Yu, the CEO and Chairman of the board of directors of AnPac Bio.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 granted patents as of December 31, 2019.

BIO Asia-Taiwan 2020 Online + Live: Finding Cures in the Crisis

Wednesday, May 13, 2020 - 1:00pm

TAIPEI, May 13, 2020 - (Media OutReach) - Taiwan BIO (Bio Industry Organization) together with BIO (the global Biotechnology Innovation Organization) announced May 7 that BIO Asia-Taiwan 2020 would go ahead as scheduled with a new online and live model; BIO Asia-Taiwan 2020 Online + Live.

Key Points: 
  • TAIPEI, May 13, 2020 - (Media OutReach) - Taiwan BIO (Bio Industry Organization) together with BIO (the global Biotechnology Innovation Organization) announced May 7 that BIO Asia-Taiwan 2020 would go ahead as scheduled with a new online and live model; BIO Asia-Taiwan 2020 Online + Live.
  • The Organizing Committee has decided that with this need, it was important to go ahead with BIO Asia-Taiwan as scheduled 22-26 July, but with activities held online with an 'online + live' approach.
  • BIO Asia-Taiwan 2020 Online + Live will again include forums and seminars, an exhibition, partnering meetings, and company presentations; this time in online formats.
  • BIO Asia-Taiwan 2020 Online + Live will focus on five topics: Combating the Pandemic, Precision Medicine, Advanced Therapies, Investment & Collaboration, and Digital Health.

2020 BIO International Convention Now Fully Digital

Friday, April 3, 2020 - 2:00pm

The Biotechnology Innovation Organization (BIO) announced today it will be moving the 2020 BIO International Convention scheduled for June 8-11 in San Diego to an online platform, in lieu of an in-person event for this year.

Key Points: 
  • The Biotechnology Innovation Organization (BIO) announced today it will be moving the 2020 BIO International Convention scheduled for June 8-11 in San Diego to an online platform, in lieu of an in-person event for this year.
  • The coronavirus is an urgent focus for the biotechnology industry as we work tirelessly to combat this public health threat, said Jim Greenwood, BIO President & CEO.
  • BIO Digital 2020 will focus on partnerships and virtual collaboration with its BIO One-on-One Partnering system allowing attendees to schedule virtual meetings using their preferred methodwhether that is a teleconference system, video meeting service, or another mediumto maximize their business development and licensing potential.
  • BIO also produces the BIO International Convention , the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

BIO Summit Accelerates Collaboration Between Government & Industry Leaders in Fight Against COVID-19

Thursday, March 26, 2020 - 5:56pm

The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating COVID-19.

Key Points: 
  • The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating COVID-19.
  • The goal is to minimize redundancies and maximize cooperation and collaboration, noted BIO President and CEO Jim Greenwood.
  • He was appointed by BIOs chairman of the board, Dr. Jeremy Levin, to oversee the organizations efforts to foster collaboration across the biopharmaceutical industry.
  • For Dr. Scangos, Greenwood, and others within BIO, the virtual summit was one step in a broader effort to combat the virus.

AnPac Bio-Medical Science Announces Cooperation with Dragon Gate Investment Partners

Tuesday, March 3, 2020 - 1:30pm

SAN JOSE, Calif., March3, 2020 /PRNewswire/ --AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company specialized in early cancer screening and detection, today announced that it has engaged Dragon Gate Investment Partners as its financial advisor.

Key Points: 
  • SAN JOSE, Calif., March3, 2020 /PRNewswire/ --AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company specialized in early cancer screening and detection, today announced that it has engaged Dragon Gate Investment Partners as its financial advisor.
  • By cooperating with Dragon Gate Investment Partners, we believe that it is a good start for us to better inform the market about our strengths, promising patents and technology, and our growth potential."
  • AnPac Bio has also engaged Dr. Michael Levitt, 2013 Nobel Laureate in Chemistry, as Chief Consultant of AnPac Bio's innovation and Technical Committee.
  • We are honored to have the opportunity to work with AnPac Bio's outstanding management team," said Ms. Lijie Zhu, Managing Director of Dragon Gate Investment Partners.

Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®

Monday, February 24, 2020 - 9:30pm

In addition, Wendy L. Dixon, Ph.D., has resigned from her position as chairwoman of the Board and member of the Board.

Key Points: 
  • In addition, Wendy L. Dixon, Ph.D., has resigned from her position as chairwoman of the Board and member of the Board.
  • Dr. Dixon will continue to serve as a CEO advisor to Sesen Bio with a focus on commercial and launch planning.
  • I am very pleased to welcome Carrie and Jason to Sesen Bios Board, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.
  • I am proud of the many milestones that the Sesen Bio team has achieved during my tenure, said Dr. Dixon.

BIO Asia Conference in Tokyo Cancelled Amid COVID-19 Outbreak

Friday, February 21, 2020 - 8:11pm

The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11.

Key Points: 
  • The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11.
  • Our attendees health and safety are our utmost priority, said Jim Greenwood, BIO President & CEO.
  • BIO will return to Japan March 9-10, 2021 for the next BIO Asia conference in Tokyo.
  • BIO also produces the BIO International Convention , the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Bio-Techne To Present At The 38th Annual J.P. Morgan Healthcare Conference

Thursday, January 2, 2020 - 12:00pm

MINNEAPOLIS, Jan. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 3:00 p.m. PST.

Key Points: 
  • MINNEAPOLIS, Jan. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 3:00 p.m. PST.
  • The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
  • A live webcast of the presentation can be accessed via Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ or through the following link https://jpmorgan.metameetings.net/events/hc20/sessions/30448-bio-techne-... .
  • With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

IVERIC bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA

Thursday, December 19, 2019 - 12:45pm

IVERIC bio, Inc. (Nasdaq: ISEE) today announced details for its R&D Investor Symposium being held in San Francisco on Tuesday, January 14, 2020, from 6:30 a.m. to 8:00 a.m. Pacific Time.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced details for its R&D Investor Symposium being held in San Francisco on Tuesday, January 14, 2020, from 6:30 a.m. to 8:00 a.m. Pacific Time.
  • A replay of the webcast will be archived on IVERIC bios website for at least 30 days following the presentation.
  • IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.

IVERIC bio to Present at the 38th Annual J.P. Morgan Healthcare Conference

Thursday, December 19, 2019 - 12:30pm

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 11:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 11:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.
  • Investors and the general public are invited to listen to a live webcast of the presentation on the Investor / Events & Presentations section of the IVERIC bio website at www.ivericbio.com .
  • IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.